Published in Expert Opin Pharmacother on September 01, 2008
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62
New perspectives in human stem cell therapeutic research. BMC Med (2009) 1.33
Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol (2011) 1.07
Stem cells and regenerative medicine: accomplishments to date and future promise. Ther Deliv (2010) 0.90
Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Front Immunol (2013) 0.84
Microenvironment at tissue injury, a key focus for efficient stem cell therapy: A discussion of mesenchymal stem cells. World J Stem Cells (2009) 0.81
The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol (2010) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol (2006) 10.33
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med (1996) 8.59
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 5.79
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Protective conditioning for acute graft-versus-host disease. N Engl J Med (2005) 4.07
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells (2006) 3.02
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A (2002) 2.91
Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest (2003) 2.85
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med (2000) 2.18
Donor APCs are required for maximal GVHD but not for GVL. Nat Med (2004) 2.18
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol (2006) 1.99
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood (2003) 1.97
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood (2007) 1.96
Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest (1999) 1.91
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A (2004) 1.85
Pathophysiology of acute graft-versus-host disease. Hematol Oncol (2003) 1.69
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood (2004) 1.58
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood (2007) 1.57
Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood (2001) 1.52
Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.50
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46
Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol (2004) 1.44
CCR2 is required for CD8-induced graft-versus-host disease. Blood (2005) 1.43
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res (2003) 1.43
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood (2004) 1.42
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant (1996) 1.41
Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood (1999) 1.36
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood (1991) 1.35
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 1.33
2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol (2005) 1.32
Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol (1997) 1.31
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant (2004) 1.30
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica (2006) 1.27
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2005) 1.23
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol (2007) 1.22
CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood (2005) 1.19
Management of acute graft-versus-host disease. Br J Haematol (2007) 1.19
Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest (2001) 1.19
Interleukin 7 worsens graft-versus-host disease. Blood (2002) 1.16
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest (2003) 1.16
Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood (2000) 1.12
Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood (2000) 1.12
IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis (2004) 1.09
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant (2004) 1.09
An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol (2004) 1.08
Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol (2005) 1.08
CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol (2000) 1.07
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood (2007) 1.07
Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica (2004) 1.06
Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol (2005) 1.06
A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood (2003) 1.03
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood (2006) 1.02
Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol (2004) 1.01
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant (2007) 1.01
CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood (2007) 0.98
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant (2005) 0.97
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant (2001) 0.97
Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J Immunol (1996) 0.97
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood (2001) 0.94
FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol (2007) 0.93
Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood (2007) 0.91
Importance of interleukin-7 in the development of experimental graft-versus-host disease. Biol Blood Marrow Transplant (2007) 0.91
Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant (2001) 0.91
Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Int Immunol (1995) 0.90
Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant (2002) 0.88
Infliximab for GVHD therapy in children. Bone Marrow Transplant (2007) 0.87
Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood (2003) 0.86
Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant (2006) 0.86
Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood (2004) 0.85
Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther (2005) 0.85
Impacts of the Cretaceous Terrestrial Revolution and KPg extinction on mammal diversification. Science (2011) 8.23
A molecular phylogeny for bats illuminates biogeography and the fossil record. Science (2005) 6.47
28-way vertebrate alignment and conservation track in the UCSC Genome Browser. Genome Res (2007) 6.42
Placental mammal diversification and the Cretaceous-Tertiary boundary. Proc Natl Acad Sci U S A (2003) 6.29
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med (2010) 4.96
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature (2012) 4.84
Initial sequence and comparative analysis of the cat genome. Genome Res (2007) 4.67
Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol (2007) 3.65
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
The late Miocene radiation of modern Felidae: a genetic assessment. Science (2006) 3.35
Effect of parental formal education on risk of child stunting in Indonesia and Bangladesh: a cross-sectional study. Lancet (2008) 3.31
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Topological Kondo insulators. Phys Rev Lett (2010) 2.66
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol (2010) 2.57
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
The mitochondrial genome sequence of the Tasmanian tiger (Thylacinus cynocephalus). Genome Res (2009) 2.30
Molecular and genomic data identify the closest living relative of primates. Science (2007) 2.26
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Proinflammatory state, hepcidin, and anemia in older persons. Blood (2010) 2.19
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med (2012) 2.13
Americans hear as well or better today compared with 40 years ago: hearing threshold levels in the unscreened adult population of the United States, 1959-1962 and 1999-2004. Ear Hear (2010) 2.04
Oxidative protein damage is associated with poor grip strength among older women living in the community. J Appl Physiol (1985) (2007) 2.04
The adequacy of morphology for reconstructing the early history of placental mammals. Syst Biol (2007) 2.03
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood (2003) 1.97
VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation (2006) 1.86
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A (2004) 1.85
mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A (2004) 1.83
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension (2009) 1.73
Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. Endocrinology (2010) 1.71
Natural killer cell subsets differentially reject embryonic stem cells based on licensing. Transplantation (2014) 1.70
AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler Thromb Vasc Biol (2006) 1.68
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood (2011) 1.68
Mesozoic origin for West Indian insectivores. Nature (2004) 1.67
A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell (2008) 1.66
A family matter: conclusive resolution of the taxonomic position of the long-fingered bats, miniopterus. Mol Biol Evol (2007) 1.62
Ecological adaptation determines functional mammalian olfactory subgenomes. Genome Res (2009) 1.59
Disorders of orthostatic blood pressure response are associated with cardiovascular disease and target organ damage in hypertensive patients. Am J Hypertens (2010) 1.58
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol (2008) 1.57
Genomics and conservation genetics. Trends Ecol Evol (2006) 1.57
High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clin Sci (Lond) (2009) 1.56
Molecular decay of the tooth gene Enamelin (ENAM) mirrors the loss of enamel in the fossil record of placental mammals. PLoS Genet (2009) 1.52
Macroevolutionary dynamics and historical biogeography of primate diversification inferred from a species supermatrix. PLoS One (2012) 1.52
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2006) 1.47
Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res (2009) 1.44
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis. Atherosclerosis (2009) 1.42
IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood (2003) 1.40
Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy (2009) 1.39
Serum antioxidants and inflammation predict red cell distribution width in older women: the Women's Health and Aging Study I. Clin Nutr (2010) 1.39
Technical comment on "The placental mammal ancestor and the post-K-Pg radiation of placentals". Science (2013) 1.39
Pattern and timing of diversification of the mammalian order Carnivora inferred from multiple nuclear gene sequences. Mol Phylogenet Evol (2010) 1.39
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
Household dietary diversity and food expenditures are closely linked in rural Bangladesh, increasing the risk of malnutrition due to the financial crisis. J Nutr (2009) 1.38
Self-assembly of synthetic hydroxyapatite nanorods into an enamel prism-like structure. J Colloid Interface Sci (2005) 1.38
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
Comparison of the sensitivity and specificity of 5 image sets of dual-energy computed tomography for detecting first-pass myocardial perfusion defects compared with positron emission tomography. Medicine (Baltimore) (2014) 1.38
Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol (2004) 1.37
Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett (2012) 1.36
Light-controlled self-assembly of semiconductor nanoparticles into twisted ribbons. Science (2010) 1.35
Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens (2008) 1.35
Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood (2011) 1.30
Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood (2003) 1.29
Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am J Clin Nutr (2010) 1.28
Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem (2011) 1.26
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26
Sun's procedure of total arch replacement using a tetrafurcated graft with stented elephant trunk implantation: analysis of early outcome in 398 patients with acute type A aortic dissection. Ann Cardiothorac Surg (2013) 1.26
An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival. Genome Res (2006) 1.25
Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood (2012) 1.25
Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci (2011) 1.25
Relationship of hepcidin with parasitemia and anemia among patients with uncomplicated Plasmodium falciparum malaria in Ghana. Am J Trop Med Hyg (2007) 1.22
Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother (2013) 1.22
Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc (2011) 1.20
Efficient cross-species capture hybridization and next-generation sequencing of mitochondrial genomes from noninvasively sampled museum specimens. Genome Res (2011) 1.18
Evidence for multiple species of Sunda colugo. Curr Biol (2008) 1.18
Mammalian evolution and biomedicine: new views from phylogeny. Biol Rev Camb Philos Soc (2007) 1.18
The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis. Mol Metab (2013) 1.17
3D honeycomb-like structured graphene and its high efficiency as a counter-electrode catalyst for dye-sensitized solar cells. Angew Chem Int Ed Engl (2013) 1.16
The historical biogeography of Mammalia. Philos Trans R Soc Lond B Biol Sci (2011) 1.15
Oxidative stress and severe walking disability among older women. Am J Med (2007) 1.15
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A (2009) 1.15
Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism. Cell (2013) 1.14
Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Curr Opin Pharmacol (2010) 1.14
Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells (2002) 1.14
Silver/dendrimer nanocomposites as biomarkers: fabrication, characterization, in vitro toxicity, and intracellular detection. Nano Lett (2005) 1.13
Cardiotonic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats. Am J Physiol Heart Circ Physiol (2010) 1.13
A high-resolution cat radiation hybrid and integrated FISH mapping resource for phylogenomic studies across Felidae. Genomics (2008) 1.13
Experimental recovery of quantum correlations in absence of system-environment back-action. Nat Commun (2013) 1.12
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med (2010) 1.12